Allergy Therapeutics PLC (DE:HHU)
FRANKFURT:HHU
HHU Stock Chart & Stats
€0.09
€0.00(0.00%)
At close: 4:00 PM EST
€0.09
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.07 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)14.35K
Market Cap
€636.82M
Enterprise Value€470.45M
Total Cash (Recent Filing)€10.08M
Total Debt (Recent Filing)€26.75M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Sep 24, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding6,332,530,000
10 Day Avg. Volume8,961
30 Day Avg. Volume14,350
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)-13.44
Price to Sales (P/S)6.88
P/FCF Ratio-11.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€778.57K
Bulls Say, Bears Say
Bulls Say
Focused Allergy Immunotherapy ModelA disease‑modifying immunotherapy focus creates durable differentiation versus symptomatic medicines. Long treatment courses, specialist prescribers and clinical evidence requirements favor stickier, recurring revenue and higher switching costs, supporting stability over months.
Allergen‑specific Product CommercializationConcentration on allergen‑specific products implies developed regulatory and commercial know‑how for a niche customer base (allergists/ENT). This specialization can improve go‑to‑market efficiency and sustain margins relative to broader, undifferentiated players over the medium term.
R&D Pipeline For Next‑generation TreatmentsMaintaining a pipeline provides durable optionality: potential product succession, IP creation and partnership/licensing avenues. Successful R&D advances can materially improve future revenue mix and reduce reliance on current products across a 2–6 month horizon and beyond.
Bears Say
Declining Revenue And Large LossesMaterial revenue decline and deep negative margins erode operational resilience. Persistent losses reduce retained earnings and increase dependence on external funding, constraining investment in commercialization and R&D and impairing the company’s ability to execute medium‑term strategies.
Negative Operating And Free Cash FlowSustained negative operating cash flow and collapsing free cash flow signal the business does not generate internal funding for growth or obligations. Over months this heightens refinancing needs, may force cost cuts or asset sales, and increases execution risk for product programs.
Stressed Balance Sheet And Negative EquityNegative equity and high leverage materially reduce financial flexibility and raise refinancing risk. Lenders and partners may impose tighter terms or covenants, increasing cost of capital and limiting strategic options for investing in commercialization or advancing the pipeline.
Allergy Therapeutics News
HHU FAQ
What was Allergy Therapeutics PLC’s price range in the past 12 months?
Allergy Therapeutics PLC lowest stock price was €0.07 and its highest was €0.16 in the past 12 months.
What is Allergy Therapeutics PLC’s market cap?
Allergy Therapeutics PLC’s market cap is €636.82M.
When is Allergy Therapeutics PLC’s upcoming earnings report date?
Allergy Therapeutics PLC’s upcoming earnings report date is Sep 24, 2026 which is in 110 days.
How were Allergy Therapeutics PLC’s earnings last quarter?
Allergy Therapeutics PLC released its earnings results on Mar 31, 2026. The company reported -€0.005 earnings per share for the quarter, the consensus estimate of -€0.005 by €0.
Is Allergy Therapeutics PLC overvalued?
According to Wall Street analysts Allergy Therapeutics PLC’s price is currently Overvalued.
Does Allergy Therapeutics PLC pay dividends?
Allergy Therapeutics PLC does not currently pay dividends.
What is Allergy Therapeutics PLC’s EPS estimate?
Allergy Therapeutics PLC’s EPS estimate is >-0.01.
How many shares outstanding does Allergy Therapeutics PLC have?
Allergy Therapeutics PLC has 6,332,530,000 shares outstanding.
What happened to Allergy Therapeutics PLC’s price movement after its last earnings report?
Allergy Therapeutics PLC reported an EPS of -€0.005 in its last earnings report, expectations of -€0.005. Following the earnings report the stock price went down -2.679%.
Which hedge fund is a major shareholder of Allergy Therapeutics PLC?
Currently, no hedge funds are holding shares in DE:HHU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Allergy Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
85.48%
12-Months-Change
Fundamentals
Return on Equity
409.00%
Trailing 12-Months
Asset Growth
-2.69%
Trailing 12-Months
Company Description
Allergy Therapeutics PLC
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
Technical Analysis
Animalcare
―
Hikma Pharmaceuticals
―
Shield Therapeutics
―
Venture Life
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Options Prices
Currently, No data available
---